Pradaxa® (dabigatran etexilate) is approved nationally and available locally
You can prescribe Pradaxa® (dabigatran etexilate) today
for your eligible patients
Pradaxa® is available for you to prescribe locally, so if you think that Pradaxa® is the right treatment for stroke prevention in your patients with NVAF, it is available for use, in line with NICE recommendations and SMC advice.1-3
National Guidelines recommend Pradaxa®
The NICE clinical guideline on the management of atrial fibrillation recommends Pradaxa® as an option for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension2,4,5
Pradaxa® is also accepted for use within NHS Scotland for this indication, as per its SMC approval.3
Praxbind®:
the specific reversal agent for Pradaxa®
Sometimes the unexpected happens and the anticoagulant effects of NOAC therapy need to be reversed. By prescribing Pradaxa®, you can have peace of mind in knowing that its effects can be reversed completely and immediately. That’s because Pradaxa® has a specific reversal agent, Praxbind®, for use in emergency surgery/urgent procedures and life-threatening or uncontrolled bleeding.6 In fact, Pradaxa® is the only NOAC with a specific antidote for use in emergency surgery/urgent procedure settings.
Pradaxa® provides savings
vs other NOACs
CCGs are under increasing pressure to make savings and with the NOAC class placed in the top 10 contributors to the total NHS medicine cost, it’s important to make savings without compromising patient health.8,9
You can help to alleviate cost pressures by prescribing Pradaxa®.
At only £1.70 a day, Pradaxa® has the lowest daily cost of all currently-available NOACs, with potential cost savings of up to £73 per patient, per year.*10
*Prices based on NHS list price.10 Annual savings per patient are calculated by multiplying the difference in the daily price of each drug relative to Pradaxa® by 365.
CCG: Clinical Commissioning Group;
NOAC: non-vitamin K antagonist oral anticoagulant;
NVAF: non-valvular atrial fibrillation;
NYHA: New York Heart Association;
SMC: Scottish Medicines Consortium.
- NICE Clinical Guideline (CG180). Atrial fibrillation: management. Published June 2014.
- NICE Technology Appraisal Guidance (TA249). Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. Published March 2012.
- SMC Advice (672/11). Dabigatran etexilate 110mg and 150mg hard capsules (Pradaxa®). Published August 2011.
- Pradaxa® 150mg hard capsules Summary of Product Characteristics.
- Pradaxa® 110mg hard capsules Summary of Product Characteristics.
- Praxbind® Summary of Product Characteristics.
- Royal College of Emergency Medicine and National Poisons Information Service. Guideline on Antidote Availability for Emergency Departments (January 2017)
- Boehringer Ingelheim. Data on File. DBG 18-01.
- Robertson R, et al. Understanding NHS financial pressures: How are they affecting patient care? The King’s Fund, London. March 2017.
- MIMS.co.uk (accessed July 2020).